|
Market Closed -
NYSE
16:00:02 2026-09-22 EDT
|
5-day change | 1st Jan Change | ||
| 1.230 USD | +9.82% |
|
+12.84% | -65.16% |
| 08-14 | ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says | MT |
| 08-13 | ADC Therapeutics SA, Q2 2026 Earnings Call, Aug 13, 2026 |
Company Valuation: ADC Therapeutics SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,550 | 306.9 | 134.1 | 192.4 | 437.3 | 143 | - | - |
| Change | - | -80.2% | -56.31% | 43.49% | 127.27% | -67.3% | - | - |
| Enterprise Value (EV) | 1,092 | 90.22 | -20.12 | 192.4 | 437.3 | 143 | 143 | 143 |
| Change | - | -91.74% | -122.31% | 1,056.12% | 127.27% | -67.3% | 0% | 0% |
| P/E | -6.73x | -1.93x | -0.56x | -1.23x | -3.15x | -1.62x | -1.82x | -4.69x |
| PBR | 9.34x | 3.49x | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | 0x | 0.1x | 0.1x | 0.2x | 0.1x |
| Capitalization / Revenue | 45.7x | 1.46x | 1.93x | 2.72x | 5.37x | 1.77x | 1.4x | 0.8x |
| EV / Revenue | 0x | 0x | -0x | 0x | 0x | 1.77x | 1.4x | 0.8x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | -0x | -0x | -1.54x | -2.24x | 34.1x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3 | -1.99 | -2.94 | -1.62 | -1.12 | -0.76 | -0.6775 | -0.2625 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 33.92 | 209.9 | 69.56 | 70.84 | 81.36 | 80.65 | 102 | 179.7 |
| EBITDA | -198.6 | -71.98 | - | - | - | - | - | - |
| EBIT 1 | -261.7 | -123.6 | -166 | -130.7 | -121.5 | -92.62 | -63.87 | 4.196 |
| Net income 1 | -230 | -155.8 | -240.1 | -157.8 | -142.6 | -119.9 | -117.8 | -50.52 |
| Net Debt | -458.5 | -216.7 | -154.2 | - | - | - | - | - |
| Reference price 2 | 20.200 | 3.840 | 1.660 | 1.990 | 3.530 | 1.230 | 1.230 | 1.230 |
| Nbr of stocks (in thousands) | 76,754 | 79,934 | 80,781 | 96,690 | 123,877 | 127,668 | - | - |
| Announcement Date | 3/3/22 | 2/28/23 | 3/13/24 | 3/27/25 | 3/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.47x | - | - | - | 143M | |
| 21.82x | 7.74x | 15.55x | 1.36% | 74.33B | |
| 32.35x | 9.35x | 29.12x | 0.04% | 62.26B | |
| 32.02x | 6.83x | 17.73x | -.--% | 27.72B | |
| -73.86x | 14.28x | -68.86x | -.--% | 26.42B | |
| -14.99x | 5.59x | -7.02x | -.--% | 24.62B | |
| 28.25x | 5.33x | 17.69x | -.--% | 20.72B | |
| 43.37x | 15.89x | 32.23x | 0.35% | 15.01B | |
| 17.67x | 5.26x | 12.29x | -.--% | 14.18B | |
| -14.6x | 3288.74x | -16.82x | -.--% | 13.48B | |
| Average | 7.06x | 373.22x | 3.54x | 0.19% | 27.89B | |
| Weighted average by Cap. | 12.52x | 167.26x | 8.13x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ADCT Stock
- Valuation ADC Therapeutics SA
Select your edition
All financial news and data tailored to specific country editions
